<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01817504</url>
  </required_header>
  <id_info>
    <org_study_id>2012.714</org_study_id>
    <nct_id>NCT01817504</nct_id>
  </id_info>
  <brief_title>Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure</brief_title>
  <acronym>DESYRE</acronym>
  <official_title>Interest of Systematic Transplantectomy Versus Conventional Care After Kidney Graft Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospices Civils de Lyon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospices Civils de Lyon</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Our hypothesis is early and systematic transplantectomy under a well-conducted
      immunosuppression is associated with a decreased risk of anti-HLA immunization against a
      conservative attitude including a gradual reduction of immunosuppression, with or without a
      transplantectomy performed for cause (clinical event).

      Observation or Investigation Method Used :

      The study is :

        -  multicenter

        -  prospective

        -  open

        -  randomized: patients are divided into two parallel groups:

             -  study group: transplantectomy within six weeks after return to dialysis,
                antiproliferatives stop at the start of dialysis, Maintenance
                anticalcineurin-based-immunosuppression without dose reduction up to two weeks
                after transplantectomy. Abrupt discontinuation of anticalcineurin two weeks after
                transplantectomy. Corticosteroids: 5mg per day until one month after
                transplantectomy then stop within one month.

             -  control group: No systematic transplantectomy. Antiproliferatives stop at the start
                of dialysis.Anticalcineurins half dose for 3 months, ¼ dose for 3 months and then
                stop. Corticosteroids:5 mg per day for 6 months, and then tapered and stop within 3
                months.

      In the case of transplantectomy for cause in the control group, immunosuppression will be
      continued at the maintenance dose during the current surgical procedure, and withdrawn two
      weeks later,similary to systematic transplantectomy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 2013</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Anti HLA Immunization assessed by Luminex assay</measure>
    <time_frame>12 months (M12)</time_frame>
    <description>Evaluate the interest of a transplantectomy early (&lt;2 months after return to dialysis) and systematic under immunosuppressive in renal transplant patients after loss of renal graft function in terms of anti-HLA immunization (measured by Luminex test) a year after loss of renal graft function and return to dialysis in the renal transplant patient.
Proportion of patients who developed HLA immunization (DSA)after systematic transplantectomy under immunosuppression versus progressive reduction of immunosuppression without transplantectomy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Kinetics anti-HLA antibodies after transplantectomy</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Determine the kinetics of new onset anti-HLA antibodies at D0, D15, D30, M3, M6, M9 after systematic or for cause transplantectomy and in the year following graft failure and the proportion of immunized patients during the first 6 months after dialysis. HLA antibodies will be assessed by Luminex test. The specificity of antibodies against HLA I or HLA II will be determined, as well as Mean Immunofluorescence Intensity in each case.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Morbidity and mortality after transplantectomy</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>Determine the morbidity and mortality after transplantectomy according to its indication, systematic or for cause (transplantectomy indications in the control group: persistent pain graft, unexplained fever, hematuria, inflammation or unexplained anemia ).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measuring the impact of systematic transplantectomy on mortality, inflammation, nutritional status, anemia, hypertension and cardiovascular risk factors</measure>
    <time_frame>12 months</time_frame>
    <description>The following parameters will be measured at D0, M1, M3, M6, M9 and M12 after return to dialysis during the first year after kidney graft failure: CRP, pre-albuminemia, albuminemia, BMI, hemoglobin, hematocrit, blood pressure, cholesterol, LDL cholesterol and triglyceride.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infectious comorbidity</measure>
    <time_frame>12 months</time_frame>
    <description>The impact of early cessation of immunosuppression on infectious complications after kidney graft failure will assessed. For each patient, origin of infection, bacterial, viral, fungal, will determined. The total number of infection episodes during the first year will be analyzed in the two groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Costs of two strategies</measure>
    <time_frame>12 months after inclusion</time_frame>
    <description>To evaluate the medico-economic impact of each conservation strategy in the management of patients who return to dialysis</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">118</enrollment>
  <condition>Renal Transplantation</condition>
  <arm_group>
    <arm_group_label>Study group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study group corresponds to systematic transplantectomy under immunosuppressive therapy within two months after return to dialysis,</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>The control group corresponds to progressive reduction of immunosuppression without systematic transplantectomy after return to dialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Systematic transplantectomy</intervention_name>
    <description>Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.</description>
    <arm_group_label>Study group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Progressive reduction of immunosuppression</intervention_name>
    <description>Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.
In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group.</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 Years.

          -  Patients affiliated to health protection system, social security in France or any
             similar regimen.

          -  Renal transplant patient with end-stage transplantation, regardless of the number of
             previous transplants.

          -  Patient receiving immunosuppressive protocol based on anticalcineurin or mTOR
             inhibitors

          -  Patient should have resume hemodialysis within 4 weeks

          -  Duration of transplantation more than one year

          -  Patient with asymptomatic graft

          -  immunogenic potential residual &gt;50% (calculated PIR during the re-dialysis)

          -  Patient not covered by any measure of legal protection.

        Exclusion Criteria:

          -  Immunogenic potential residual &lt;50%

          -  Graft infection uncontrolled by treatment

          -  Active infectious pathology

          -  Inflammatory graft

          -  Uncontrolled arterial hypertention

          -  Inflammatory syndrome of undetermined origin with CRP&gt;50mg/l

          -  Fever of unknown origin for more than 8 days T&gt;38°C

          -  Contra-indication to surgery

          -  AVK treatment

          -  Patient candidate for a living donor within 12 months

          -  Monotherapy with calcineurin inhibitors or mTOR inhibitors

          -  Treatment directed against the humoral response in the 6 months preceding the recovery
             of dialysis (Rituximab IV-Ig or high doses)

          -  Presence of another transplant (pancreas, liver, heart, lung)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emmanuel MORELON, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Transplantation Department, Hopital Edouard Herriot, Hospices Civils de Lyon</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Emmanuel MORELON, MD</last_name>
    <phone>472 110 150</phone>
    <phone_ext>+33</phone_ext>
    <email>emmanuel.morelon@chu-lyon.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Néphrologie, Médecine interne, Hémodialyse, Transplantation Rénale, Hôpital Sud</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabriel CHOUKROU, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gabriel CHOUKROU, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie, Dialyse et Transplantation - Hôpital Jean Minjoz</name>
      <address>
        <city>Besançon</city>
        <zip>25030</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Didier DUCLOUX, MD</last_name>
    </contact>
    <investigator>
      <last_name>Didier DUCLOUX, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie - Hôpital de La Cavale blanche</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yannick LE MEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Yannick LE MEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie et Transplantation Rénale, CHU Gabriel Montpied</name>
      <address>
        <city>Clermont-Ferrand Cedex</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne-Elisabeth HENG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anne-Elisabeth HENG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpitaux Civils de Colmar</name>
      <address>
        <city>Colmar</city>
        <zip>68024</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre KLEIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre KLEIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie -Dialyse-Transplantation, Hôpital Michallon</name>
      <address>
        <city>Grenoble Cedex</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paolo MALVEZZI, MD</last_name>
    </contact>
    <investigator>
      <last_name>Paolo MALVEZZI, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Haguenau</name>
      <address>
        <city>Haguenau</city>
        <zip>67504</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc KRIBS, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc KRIBS, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier départemental Vendée - Site de la Roche-sur-Yon</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Grégoire COUVRAT-DESVERGNES, MD</last_name>
    </contact>
    <investigator>
      <last_name>Grégoire COUVRAT-DESVERGNES, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie - Hôpital Claude Huriez</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc HAZZAN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marc HAZZAN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Transplantation Department, Hôpital Edourad Herriot</name>
      <address>
        <city>Lyon</city>
        <zip>69003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emmanuel MORELON, MD</last_name>
      <phone>33 472 110 150</phone>
      <phone_ext>+33</phone_ext>
      <email>emmanuel.morelon@chu-lyon.fr</email>
    </contact>
    <investigator>
      <last_name>Emmanuel MORELON, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie et Transplantation Rénale - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie GARRIGUE, MD</last_name>
    </contact>
    <investigator>
      <last_name>Valérie GARRIGUE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Institut de Transplantation, Urologie et Néphrologie - CHU Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gilles BLANCHO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Gilles BLANCHO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Unité de Transplantation Rénale - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elisabeth CASSUTO, MD</last_name>
    </contact>
    <investigator>
      <last_name>Elisabeth CASSUTO, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Urgence Néphrologique et Transplantation Rénale - Hôpital Tenon</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alexandre HERTIG, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alexandre HERTIG, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie, Centre Hospitalier Lyon Sud</name>
      <address>
        <city>Pierre Bénite</city>
        <zip>69310</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solenne PELETTIER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Solenne PELETTIER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie-Dialyse, Centre Hospitalier d'Annecy</name>
      <address>
        <city>Pringy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maizé DUCRET, MD</last_name>
    </contact>
    <investigator>
      <last_name>Maizé DUCRET, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie, Dialyse et Transplantation Rénale, Hôpital Nord</name>
      <address>
        <city>Saint-Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christophe MARIAT, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christophe MARIAT, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie et Transplantation Rénale - Nouvel Hôpital Civil</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bruno MOULIN, MD</last_name>
    </contact>
    <investigator>
      <last_name>Bruno MOULIN, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Département de Néphrologie et Transplantation d'Organes - Hôpîtal Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Service de Néphrologie, Immunologie Clinique - CHU Bretonneau</name>
      <address>
        <city>Tours</city>
        <zip>37044</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias BUCHLER, MD</last_name>
    </contact>
    <investigator>
      <last_name>Matthias BUCHLER, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 8, 2013</study_first_submitted>
  <study_first_submitted_qc>March 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 25, 2013</study_first_posted>
  <last_update_submitted>May 25, 2018</last_update_submitted>
  <last_update_submitted_qc>May 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Renal failure,</keyword>
  <keyword>Transplantectomy</keyword>
  <keyword>Immunosuppression</keyword>
  <keyword>Sensitization</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

